Fagron NV (LON:0HNZ)

Market Cap	1.41B
Revenue (ttm)	721.08M
Net Income (ttm)	66.62M
Shares Out	n/a
EPS (ttm)	0.91
PE Ratio	21.21
Forward PE	16.72
Dividend	0.21 (0.92%)
Ex-Dividend Date	May 19, 2025

Volume	23
Average Volume	3,430
Open	22.45
Previous Close	22.30
Day's Range	22.30 - 22.45
52-Week Range	15.84 - 22.90
Beta	0.24
RSI	55.85
Earnings Date	Jul 31, 2025

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointest...

• Industry: Medical, Dental, and Hospital Equipment and Supplies
• Founded: 1990
• Employees: 3,828
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HNZ

Financial Performance

In 2024, Fagron NV's revenue was 871.96 million, an increase of 14.28% compared to the previous year's 762.99 million. Earnings were 80.55 million, an increase of 14.18%.

Financial numbers in EUR